New Homepage

Thank you for another great meeting!

New Advances in the Assessment of Drug-Induced Arrhythmias and the Comprehensive In Vitro Proarrhythmia Assay (CiPA)

The wait is over!
Download the presentation slides and read the meeting synopsis.

September 7

Defining the Clinical and Regulatory Landscape for Cardiogenic Shock

View Meeting Details and Draft Agenda

October 10

CSRC-DIA Mobile Technologies Think Tank: Use of Mobile Technologies in Clinical Trials for Assessment of Cardiovascular Endpoints

View Meeting Details

The Cardiac Safety Research Consortium is dedicated to advancing scientific knowledge on cardiac safety for new and existing medical products by building a collaborative environment based upon the principles of the FDA’s Critical Path Initiative as well as other public health priorities.

Upcoming Events

We're planning for the following meetings in 2018:

Summer
June 24-25: DIA Global Annual Meeting: Short Course Sessions with CSRC members Mary Jane Geiger, Mitch Krucoff, Philip Sager, Norman Stockbridge, and Rick Turner

August: Follow-up think tank regarding the FDA's draft Guidance for Industry titled, “Assessment of Pressor Effects of Drugs."

VIEW DETAILS


Fall
September 7: Defining the Clinical and Regulatory Landscape for Cardiogenic Shock

VIEW DETAILS

October 10: Use of Mobile Technologies in Clinical Trials for Assessment of Cardiovascular Endpoints

VIEW DETAILS

 

News & Updates

June 2018 CiPA Update Available

View the message from Jennifer Pierson, HESI senior scientific program manager, on behalf of the CiPA Steering Team.

Announcement of Interest in the Domain of Drug Cardiovascular Safety

Read the CSRC statement regarding the FDA's draft guidance.

Find us in Cardiology Today!

Learn more about stem cell therapies for cardiovascular diseases in our article published in Cardiology Today.

 

Never miss a beat.
Follow the cardiac safety conversation on Twitter at @CardiacSafety.
Circle-Group

Initiatives and Projects

For more than a decade, we have made great strides in advancing knowledge of cardiac safety in clinical research through conferences, publications, and research projects. We are currently planning for the following think tanks in 2018:

New Advances in the Assessment of Drug-Induced Arrhythmias and the Comprehensive In Vitro Proarrythmia Assay (CiPA) (Spring)

Understanding Cardiogenic Shock and Defining the Concept of “Pre-shock” (Fall)

  • Concept of "pre-shock" and develop consensus statements for clinical/research use
  • Mechanical circulatory support in treating "pre-shock"

Novel Approaches for the Evaluation of Mobile Technologies in CV Medicine — Scientific rigor, Innovative Methods, Regulatory Acceptance (Fall)

  • Integrating devices into supporting cardiovascular safety and efficacy endpoints
  • Promised efficiencies of mobile technology in clinical trials
  • Device features, patient features, endpoint validation, and regulatory considerations

Submit Your Ideas

SUBMIT YOUR IDEAS FOR THINK TANKS AND PUBLICATIONS

In order to promote the spirit of collaboration the CSRC highly values, we ask that you submit your ideas for future research projects, think tanks, and white papers. By hearing directly from our members, we can ensure that the topics researched, discussed and published are important to you.

HELD 48 SCIENTIFIC MEETINGS PRODUCED 46 PUBLICATIONS COMPLETED 14 PROJECTS, FORMED 6 COLLABORATIVE COMMITTES, CREATED ECG WAREHOUSE & NON-CV CRFs, RESEARCHED VARIOUS CARDIAC SAFETY TOPICS

Submit

Join

CSRC members benefit from engaging in pre-competitive collaboration with cardiac safety professionals on vital research topics and projects. Working together, we have the opportunity to accomplish public health objectives that no single stakeholder could achieve on its own. The CSRC takes to heart the African proverb shared at one of our pediatric safety think tanks:
If you want to go fast, go alone. If you want to go far, go together.

In that spirit, we celebrate our second decade of excellence in
cardiac safety research, and going there together.